XML 44 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance Sheet Account Detail (Tables)
 6 Months Ended
Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Cash And Cash Equivalent Marketable Securities Unrealized Gain Table
The following is a summary of our presented “cash and cash equivalents” and “marketable securities”:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cost
 
Foreign Currency Translation
 
Gross
Unrealized
Gains*
 
Gross
Unrealized
Losses
 
Estimated
Fair
Value
 
Cash and Cash
Equivalents
 
Marketable Securities
June 30, 2018
 
 

 
 
 
 
 
 
 
 
 
 
Equity securities* (see Note 3(g) and Note 10)
$
8,710

 
$
(1,747
)
 
$
88,075

 
$
—

 
$
95,038

 
$
—

 
$
95,038

Bank deposits
10,769

 
—

 
—

 
—

 
10,769

 
10,769

 
—

Money market funds
163,602

 
—

 
—

 
—

 
163,602

 
163,602

 
—

Bank certificates of deposits
249

 
—

 
—

 
—

 
249

 
—

 
249

Total cash and cash equivalents and marketable securities
$
183,330

 
$
(1,747
)
 
$
88,075

 
$
—

 
$
269,658

 
$
174,371

 
$
95,287

December 31, 2017
 
 

 
 
 
 
 
 
 
 
 
 
Bank deposits
$
10,965

 
$
—

 
$
—

 
$
—

 
$
10,965

 
$
10,965

 
$
—

Money market funds
216,358

 
—

 
—

 
—

 
216,358

 
216,358

 
—

Bank certificates of deposits
248

 
—

 
—

 
—

 
248

 
—

 
248

Total cash and cash equivalents and marketable securities
$
227,571

 
$
—

 
$
—

 
$
—

 
$
227,571

 
$
227,323

 
$
248


* Beginning January 1, 2018, under the new requirements of ASU 2016-01, Recognition and Measurement of Financial Assets and Liabilities, the unrealized gains (losses) on our CASI Pharmaceuticals, Inc. (NASDAQ: CASI) (“CASI”) equity securities are recognized as an increase (decrease) to “other income, net” on the Consolidated Statements of Operations (rather than through “other comprehensive (loss) income” on the Consolidated Statements of Comprehensive Loss). Our adoption of ASU 2016-01 on January 1, 2018, resulted in a $17.2 million cumulative-effect adjustment, net of income tax, recorded as a decrease to “accumulated other comprehensive (loss) income” and a decrease to “accumulated deficit” on the accompanying Condensed Consolidated Balance Sheets. Our recognized unrealized gain on these equity securities for the three and six months ended June 30, 2018 was $48.5 million and $58.6 million, respectively, as reported in “other income, net” on the accompanying Condensed Consolidated Statements of Operations.
Schedule of Property and Equipment Net of Accumulated Depreciation
“Property and equipment, net of accumulated depreciation” consists of the following: 
 
June 30, 2018
 
December 31, 2017
Computer hardware and software
$
3,080

 
$
2,994

Laboratory equipment
635

 
630

Office furniture
212

 
218

Leasehold improvements
2,938

 
2,938

Property and equipment, at cost
6,865

 
6,780

(Less): Accumulated depreciation
(6,342
)
 
(6,191
)
Property and equipment, net of accumulated depreciation
$
523

 
$
589
Components of Inventories
“Inventories” consists of the following: 
 
June 30, 2018
 
December 31, 2017
Raw materials
$
2,149

 
$
1,077

Work-in-process
3,204

 
2,551

Finished goods
2,647

 
5,187

(Less:) Non-current portion of inventories included within "other assets" *
(3,480
)
 
(3,100
)
Inventories
$
4,520

 
$
5,715


* The “non-current” portion of inventories is presented within “other assets” in the accompanying Condensed Consolidated Balance Sheets at June 30, 2018 and December 31, 2017, respectively. This value of $3.5 million at June 30, 2018 represents product that we expect to sell beyond June 30, 2019 and the value at December 31, 2017 represents product that we expect to sell beyond December 31, 2018.
.
Prepaid Expenses and Other Assets
“Prepaid expenses and other assets” consists of the following:
 
June 30, 2018
 
December 31, 2017
Other miscellaneous prepaid operating expenses
$
3,900

 
$
3,389

Prepaid insurance
761

 
645

Research and development supplies
108

 
1,883

Key employee life insurance - cash surrender value
—

 
4,150

Prepaid expenses and other assets
$
4,769

 
$
10,067
Schedule of Other Receivables
“Other receivables” consists of the following:
 
June 30, 2018
 
December 31, 2017
Other miscellaneous receivables*
$
968

 
$
1,152

Income tax receivable
638

 
665

Insurance receivable
1,130

 
53

Reimbursements due from development partners for incurred research and development expenses
179

 
263

Other receivables
$
2,915

 
$
2,133


* As of June 30, 2018 and December 31, 2017, the balance is inclusive of $0.4 million and $0.4 million, respectively, of Medicaid rebate credits to be applied against future invoices for each respective state program, and $0.2 million and $0.4 million, respectively, of royalty receivables from Mundipharma International Corporation Limited (“Mundipharma”) for sales of ZEVALIN in Japan.
Components of Intangible Assets Net of Accumulated Amortization
Intangible assets, net of accumulated amortization and impairment charges consists of the following: 
 
 
 
June 30, 2018
 
Historical
Cost
 
Accumulated
Amortization
 
Foreign
Currency
Translation
 
Impairment
 
Net Amount
 
Full
Amortization
Period
(months)
 
Remaining
Amortization
Period
(months)
MARQIBO IPR&D (NHL and other novel indications)
$
17,600

 
$
—

 
$
—

 
$
—

 
$
17,600

 
n/a
 
n/a
EVOMELA distribution rights
7,700

 
(1,333
)
 
—

 
—

 
6,367

 
156
 
129
BELEODAQ distribution rights
25,000

 
(7,500
)
 
—

 
—

 
17,500

 
160
 
112
MARQIBO distribution rights
26,900

 
(19,342
)
 
—

 
—

 
7,558

 
81
 
21
FOLOTYN distribution rights (1)
118,400

 
(60,649
)
 
—

 
—

 
57,751

 
152
 
53
ZEVALIN distribution rights – U.S.
41,900

 
(39,294
)
 
—

 
—

 
2,606

 
123
 
9
ZEVALIN distribution rights – ex-U.S.
23,490

 
(17,624
)
 
(2,994
)
 
—

 
2,872

 
96
 
21
FUSILEV distribution rights (2)
16,778

 
(9,618
)
 
—

 
(7,160
)
 
—

 
56
 
0
FOLOTYN out-license (3)
27,900

 
(15,917
)
 
—

 
(1,023
)
 
10,960

 
110
 
49
Total intangible assets
$
305,668

 
$
(171,277
)
 
$
(2,994
)
 
$
(8,183
)
 
$
123,214

 
 
 
 
 
(1)
Beginning June 2016, we adjusted the amortization period of our FOLOTYN distribution rights to November 2022 from March 2025, representing the period through which we expect to have patent protection from generic competition (see Note 16(g)).

(2)
On February 20, 2015, the United States District Court for the District of Nevada found the patent covering FUSILEV to be invalid, which was upheld on appeal. On April 24, 2015, Sandoz began to commercialize a generic version of FUSILEV. This represented a “triggering event” under applicable GAAP in evaluating the value of our FUSILEV distribution rights as of March 31, 2015, resulting in a $7.2 million impairment charge (non-cash) in the first quarter of 2015. We accelerated amortization expense recognition in 2015 for the then remaining net book value of FUSILEV distribution rights.

(3)
On May 29, 2013, we amended our FOLOTYN collaboration agreement with Mundipharma. As a result of the amendment, Europe and Turkey were excluded from Mundipharma’s commercialization territory, and their royalty rates and milestone payments to us were modified. This constituted a change under which we originally valued the FOLOTYN out-license as part of business combination accounting, resulting in an impairment charge (non-cash) of $1.0 million in the second quarter of 2013.

 
 
 
December 31, 2017

Historical
Cost
 
Accumulated
Amortization
 
Foreign
Currency
Translation
 
Impairment
 
Net Amount
MARQIBO IPR&D (NHL and other novel indications)
$
17,600

 
$
—

 
$
—

 
$
—

 
$
17,600

EVOMELA distribution rights
7,700

 
(1,037
)
 
—

 
—

 
6,663

BELEODAQ distribution rights
25,000

 
(6,563
)
 
—

 
—

 
18,437

MARQIBO distribution rights
26,900

 
(17,182
)
 
—

 
—

 
9,718

FOLOTYN distribution rights
118,400

 
(54,111
)
 
—

 
—

 
64,289

ZEVALIN distribution rights – U.S.
41,900

 
(37,557
)
 
—

 
—

 
4,343

ZEVALIN distribution rights – Ex-U.S.
23,490

 
(17,232
)
 
(2,471
)
 
—

 
3,787

FUSILEV distribution rights
16,778

 
(9,618
)
 
—

 
(7,160
)
 
—

FOLOTYN out-license
27,900

 
(14,555
)
 
—

 
(1,023
)
 
12,322

Total intangible assets
$
305,668

 
$
(157,855
)
 
$
(2,471
)
 
$
(8,183
)
 
$
137,159
Estimated Intangible Asset Amortization Expense
Estimated intangible asset amortization expense for the remainder of 2018 and the five succeeding fiscal years and thereafter is as follows:

Years Ending December 31,
 
Remainder of 2018
$
13,850

2019
25,095

2020
19,756

2021
18,266

2022
15,882

2023
2,467

2024 and thereafter
10,298

 
$
105,614
Schedule of Goodwill
“Goodwill” consists of the following:
 
June 30, 2018
 
December 31, 2017
Acquisition of Talon (MARQIBO rights)
$
10,526

 
$
10,526

Acquisition of ZEVALIN Ex-U.S. distribution rights
2,525

 
2,525

Acquisition of Allos (FOLOTYN rights)
5,346

 
5,346

Foreign currency exchange translation effects
(291
)
 
(235
)
Goodwill
$
18,106

 
$
18,162
Summary of Other Assets
“Other assets” consists of the following: 
 
June 30, 2018
 
December 31, 2017
Equity securities (see Note 10)*
$
—

 
$
37,530

Key employee life insurance – cash surrender value
6,123

 
10,737

Inventories - non-current portion
3,480

 
3,100

Promissory note receivable - long term (see Note 10)
1,521

 
1,517

Income tax receivable**
668

 
668

Research & development supplies and other
1,367

 
231

Other assets
$
13,159

 
$
53,783

* As of March 31, 2018, we reclassified our presentation of these equity securities from this account caption to “marketable securities” on the face of our accompanying Condensed Consolidated Balance Sheets - see Note 3(a).
** This value represents the non-current portion of the refundable alternative minimum tax credit that is expected to be received over the next few years (see Note 16).
Schedule of Accounts Payable and Other Accrued Liabilities
“Accounts payable and other accrued liabilities” consists of the following:
 
June 30, 2018
 
December 31, 2017
Trade accounts payable and other accrued liabilities
$
29,370

 
$
33,648

Accrued rebates
6,904

 
7,990

Accrued product royalty
3,427

 
4,339

Allowance for returns
4,378

 
4,045

Accrued data and distribution fees
3,036

 
4,305

Accrued GPO administrative fees
230

 
296

Accrued inventory management fee
799

 
1,126

Allowance for chargebacks
1,742

 
2,368

Accounts payable and other accrued liabilities
$
49,886

 
$
58,117
Schedule of Amounts Presented in Accounts Payable and Other Accrued Liabilities
Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Condensed Consolidated Balance Sheets for our categories of GTN estimates (see Note 2(i)) were as follows:

Commercial/Medicaid Rebates and Government Chargebacks
 
Distribution, Data, Inventory and
GPO Administrative Fees
 
Product Return Allowances
Balance as of December 31, 2016
$
9,817

 
$
5,146

 
$
2,309

Add: provisions
106,647

 
20,104

 
2,807

(Less): credits or actual allowances
(106,106
)
 
(19,523
)
 
(1,071
)
Balance as of December 31, 2017
10,358

 
5,727

 
4,045

Add: provisions
33,083

 
7,094

 
898

(Less): credits or actual allowances
(34,795
)
 
(8,756
)
 
(565
)
Balance as of June 30, 2018
$
8,646

 
$
4,065

 
$
4,378
Deferred Revenue, by Arrangement, Disclosure
Deferred revenue (current and non-current) consists of the following:

June 30, 2018
 
December 31, 2017
EVOMELA deferred revenue
$
—

 
$
3,819

ZEVALIN out-license in India territory (see Note 15(b)(iii))
—

 
368

Deferred revenue*
$
—

 
$
4,187

* On January 1, 2018, we reclassified the deferred revenue related to our EVOMELA product sales and our ZEVALIN out-license in the India territory of $3.8 million and $0.4 million, respectively. These amounts were included in the $4.7 million aggregate decrease to “accumulated deficit” on January 1, 2018, in accordance with the adoption of Topic 606 (see Note 2(i)).
Summary of Other Long-Term Liabilities
“Other long-term liabilities” consists of the following:
 
June 30, 2018
 
December 31, 2017
Accrued executive deferred compensation
$
5,212

 
$
5,928

Deferred rent (non-current portion)
1

 
52

Clinical study holdback fees, non-current
62

 
59

Other tax liabilities
176

 
176

Royalty liability
300

 
—

Other long-term liabilities
$
5,751

 
$
6,215